Page last updated: 2024-11-06

tianeptine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tianeptine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tianeptine : A racemate comprising of equimolar amounts of (R)- and (S)-tianeptine. It is an atypical antidepressant used in Europe to treat patients who respond poorly to selective serotonin reuptake inhibitors (SSRIs). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid : A member of the class of dibenzothiazepines that is 3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide substituted by a (6-carboxyhexyl)amino group at position 11. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

(S)-tianeptine : The S-enantiomer of tianeptine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID23663953
CHEMBL ID2361572
SCHEMBL ID2433840
MeSH IDM0144175
PubMed CID68870
CHEMBL ID1289110
CHEBI ID190006
CHEBI ID190008
CHEBI ID91749
SCHEMBL ID49293
MeSH IDM0144175

Synonyms (153)

Synonym
AC-930
HY-90003A
tianeptine (sodium salt)
HMS3268B13
tianeptine sodium ,
stablon
stablon (tn)
30123-17-2
NCGC00167725-01
coaxil
D08589
(+)-tianeptine monosodium salt
169293-32-7
54317-11-2
einecs 259-091-2
sodium (1)-7-((3-chloro-6,11-dihydro-6-methyldibenzo(c,f)(1,2)thiazepin-11-yl)amino)heptanoate s,s-dioxide
dtxcid2026737
cas-30123-17-2
dtxsid4046737 ,
tox21_112580
A820215
7-[(3-chloro-6-methyl-5,5-dioxo-11h-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoate; sodium
einecs 250-059-3
tatinol
yg0e19592i ,
tianeptine sodium salt ,
unii-yg0e19592i
tianeptine sodium salt hydrate
7-[(3-chloro-6,11-dihydro-6-methyl-dibenzo[c,f][1,2]thiazepine-11-yl)amino]heptanoic acid s,s dioxide sodium salt hydrate
FT-0630553
CS-0434
S1436
AKOS015900612
c21h24cln2nao4s
T3131
KS-1218
sodium 7-(((11 rs)-3-chloro-6-methyl-6,11-dihydrodibenzo(c,f)(1,2)thiazepin-11-yl)amino)heptanoate s,s-dioxide
tianeptine sodium salt [mi]
heptanoic acid, 7-((3-chloro-6,11-dihydro-6-methyl-5,5-dioxidodibenzo(c,f)(1,2)thiazepin-11-yl)amino)-, sodium salt (1:1)
tianeptine sodium [ep monograph]
tianeptine sodium [mart.]
tianeptine sodium [who-dd]
SCHEMBL2433840
sodium 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoate
7-[(3-chloro-6,11-dihydro-6-methyl-5,5-dioxidodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid sodium salt
Q-100384
7-[(3-chloro-6,11-dihydro-6-methyl- 5,5-dioxidodibenzo[c,f][1,2]thiazepin-11-yl)amino] heptanoic acid sodium salt
HB1704
heptanoic acid, 7-((3-chloro-6,11-dihydro-6-methyl-5,5-dioxidodibenzo(c,f)(1,2)thiazepin-11-yl)amino)-, monosodium salt, (-)-
tianeptine sodium, (-)-
heptanoic acid, 7-((3-chloro-6,11-dihydro-6-methyl-5,5-dioxidodibenzo(c,f)(1,2)thiazepin-11-yl)amino)-, monosodium salt, (+)-
7LI031265R ,
tianeptine sodium, (+)-
heptanoic acid, 7-((3-chloro-6,11-dihydro-6-methyldibenzo(c,f)(1,2)thiazepin-11-yl)amino)-, s,s-dioxide, monosodium salt, (+)-
ROJ48D5596
CHEMBL2361572 ,
7-[[3-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl]amino]heptanoic acid s,s-dioxide sodium salt
unii-7li031265r
sodium 7-((3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino)heptanoate
HMS3651G11
SW219882-1
30123-17-2 (sodium)
(e)-n-(3-chlorobenzylidene)aniline
FT-0675217
HMS3676P12
coaxil sodium salt
BCP10100
HMS3412P12
HMS3884O15
AMY393
CCG-269325
sodium;7-[(3-chloro-6-methyl-5,5-dioxo-11h-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoate
tianeptine na
BT164468
tianeptine sodium- bio-x
AC-2091
HY-90003
s-1574 ,
D02575
tianeptine (inn)
66981-73-5
(3-chloro-6-methyl-5,5-dioxo-6,11-dihydrodibenzo(c,f)(1,2)thiazepin-11-yl)-7-aminoheptanoic acid
tianeptine
tianeptina [inn-spanish]
7-((3-chloro-6,11-dihydro-6-methyldibenzo(c,f)(1,2)thiazepin-11-yl)amino)heptanoic acid s,s-dioxide
tianeptine [inn]
7-[(3-chloro-6-methyl-5,5-dioxo-11h-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoic acid
7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid
7-[(3-chloro-6,11-dihydro-6-methyl-5,5-dioxidodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid
CHEBI:190006
7-[(3-chloro-6-methyl-5,5-dioxo-6,11-dihydro-5h-5lambda(6)-dibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid
CHEBI:190008
(s)-tianeptine
7-{[(11s)-3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl]amino}heptanoic acid
A835601
7-[[3-chloranyl-6-methyl-5,5-bis(oxidanylidene)-11h-benzo[c][2,1]benzothiazepin-11-yl]amino]heptanoic acid
tianeptine acid
tpi-1062
CHEMBL1289110
jnj-39823277
FT-0675218
72797-41-2
0t493yfu8o ,
(1)-7-((3-chloro-6,11-dihydro-6-methyldibenzo(c,f)(1,2)thiazepin-11-yl)amino)heptanoic acid s,s-dioxide
tianeptina
unii-0t493yfu8o
einecs 276-851-9
FT-0630770
CS-0433
AKOS015900590
S5087
BRD-A53077924-236-01-4
gas station heroin
tianeptine [mi]
tianeptine [nflis-drug]
tianeptine [who-dd]
gtpl7558
SCHEMBL49293
MLS006010111
smr004701247
KS-5099
DTXSID7048295
Q-100759
s-16190
tianeptine, (+)-
heptanoic acid, 7-((3-chloro-6,11-dihydro-6-methyldibenzo(c,f)(1,2)thiazepin-11-yl)amino)-, s,s-dioxide, (+)-
tianeptine, (-)-
191172-75-5
XV6773012I ,
s-16191
(-)-tianeptine
heptanoic acid, 7-((3-chloro-6,11-dihydro-6-methyl-5,5-dioxidodibenzo(c,f)(1,2)thiazepin-11-yl)amino)-, (-)-
169293-31-6
AKU7QFL9ZT ,
(+)-tianeptine
heptanoic acid, 7-((3-chloro-6,11-dihydro-6-methyl-5,5-dioxidodibenzo(c,f)(1,2)thiazepin-11-yl)amino)-, (+)-
DB09289
unii-aku7qfl9zt
unii-xv6773012i
7-[(6-chloro-10-methyl-9,9-dioxo-9$l^{6}-thia-10-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3(8),4,6,11,13-hexaen-2-yl)amino]heptanoic acid
CHEBI:91749
EX-A2724
Q424260
7-((3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino)heptanoic acid
tianeptineacid
mfcd00865376
ZB1716
BCP10101
HMS3886A13
CCG-269088
C76315
A914696
7-[[(11r)-3-chloro-6-methyl-5,5-dioxo-11h-benzo[c][2,1]benzothiazepin-11-yl]amino]heptanoic acid

Research Excerpts

Overview

Tianeptine is an atypical antidepressant used in Europe to treat patients who respond poorly to selective serotonin reuptake inhibitors (SSRIs) It is a mu-opioid receptor (MOR) agonist with increasing reports of abuse in human populations.

ExcerptReferenceRelevance
"Tianeptine is an atypical antidepressant used in Europe to treat patients who respond poorly to selective serotonin reuptake inhibitors (SSRIs). "( Mu opioid receptors on hippocampal GABAergic interneurons are critical for the antidepressant effects of tianeptine.
Allain, F; Andreu, V; Grinnell, SG; Han, J; Harris, AZ; Hen, R; Javitch, JA; Kieffer, BL; Langreck, C; Magalong, V; Nautiyal, KM; Pekarskaya, EA; Pintar, J, 2022
)
2.38
"Tianeptine is a mu-opioid receptor (MOR) agonist with increasing reports of abuse in human populations. "( Opioid-like adverse effects of tianeptine in male rats and mice.
Akbarali, HI; Baird, TR; Dewey, WL; Elder, H; Kang, M; Marsh, SA; Negus, SS; Peace, MR; Poklis, JL; Santos, EJ, 2022
)
2.45
"Tianeptine is an atypical antidepressant that is not approved for use in the United States and has a significant potential for abuse. "( Nursing Implications for Tianeptine Use and Misuse.
Hargett, JL; Lee, KN; Lowry, PF,
)
1.88
"Tianeptine (TIAN) is an atypical antidepressant that activates the mu-opioid receptor but does not produce analgesic tolerance or withdrawal in mice, nor euphoria in humans, at clinically-relevant doses."( Tianeptine promotes lasting antiallodynic effects in a mouse model of neuropathic pain.
Estill, M; Javitch, JA; Pekarskaya, EA; Sakloth, F; Serafini, RA; Shen, L; Zachariou, V, 2023
)
3.07
"Tianeptine is an atypical mu-opioid receptor agonist. "( Tianeptine Abuse Leading to an Episode of Psychosis: A Case Report and Literature Review.
Ioannou, C; Karim, A, 2020
)
3.44
"Tianeptine is an antidepressant structurally similar to tricyclic antidepressants which is approved abroad but is currently a drug of abuse in the United States since at least 2000. "( Characteristics of tianeptine effects reported to a poison control center: a growing threat to public health.
Brown, J; Kurz, M; Rivera, J; Rushton, W; Whitworth, B, 2021
)
2.39
"Tianeptine is an antidepressant that exhibits structural similarities to tricyclic antidepressants but has distinct neurochemical properties."( Tianeptine Reduces Mechanical Allodynia in Spinal Nerve-ligated and Chemotherapy-induced Neuropathic Mice.
Han, SM; Jo, HU; Kim, YH; Kwak, JA; Park, HJ, 2017
)
2.62
": Tianeptine is a tricyclic antidepressant that stimulates mu-opioid receptors at high doses. "( Online Sales of Unscheduled Pharmaceutical Agents: A Case Report of Tianeptine Use in the United States.
Gupta, S; Sloshower, J; Wallace, R,
)
1.09
"Tianeptine is a clinically effective atypical antidepressant with distinct neurochemical properties. "( Opioid Receptors Contribute to Antinociceptive Effect of Tianeptine on Colorectal Distension-Induced Visceral Pain in Rats.
Bilge, SS; Bozkurt, A; Çiftcioğlu, E; Darakcı, Ö; İlkaya, F, 2018
)
2.17
"Tianeptine is an atypical antidepressant with a unique mechanism of action and recently it has been also reported that its major metabolite, compound MC5, possesses pharmacological activity similar to that of the parent drug. "( Pharmacokinetic study of tianeptine and its active metabolite MC5 in rats following different routes of administration using a novel liquid chromatography tandem mass spectrometry analytical method.
Fedak, FA; Pociecha, K; Szafarz, M; Wencel, A; Wlaź, P; Wyska, E, 2018
)
2.23
"Tianeptine is an atypical antidepressant approved in 25 countries for the treatment of depressive syndromes. "( Tianeptine Abuse and Dependence in Psychiatric Patients: A Review of 18 Case Reports in the Literature.
Cubała, WJ; Springer, J,
)
3.02
"Tianeptine is a tricyclic anti-depressant that is also known to have opioid receptor activity. "( Case Reports of Fatalities Involving Tianeptine in the United States.
Bakota, EL; Gray, TR; Hines, MO; Oleske, DA; Samms, WC, 2018
)
2.2
": Tianeptine is an atypical antidepressant which exerts an opioid-like effect on the μ-opioid receptor. "( Use of Buprenorphine-Naloxone in the Treatment of Tianeptine Use Disorder.
Trowbridge, P; Walley, AY,
)
1.11
"Tianeptine is an antidepressant, with anxiolytic properties, that can improve somatic symptoms."( Tianeptine, an atypical pharmacological approach to depression.
Alamo, C; García-Garcia, P; Lopez-Muñoz, F; Zaragozá, C,
)
2.3
"Tianeptine is an atypical antidepressant drug, augmenting serotonin reuptake and preventing stress-associated changes in the brain. "( Possible usefulness of tianeptine in treatment-resistant depression.
Rybakowski, JK; Tobe, EH, 2013
)
2.14
"Tianeptine is an agent that challenges the traditional monoaminergic hypothesis of antidepressant action, though its exact mode of action remains controversial."( Tianeptine in an experimental medicine model of antidepressant action.
Cooper, CM; Cowen, PJ; Harmer, CJ; Whiting, DA, 2015
)
2.58
"Tianeptine is an atypical antidepressant drug with proven clinical efficacy, but its mechanism of action remains still not fully understood."( Anti-inflammatory properties of tianeptine on lipopolysaccharide-induced changes in microglial cells involve toll-like receptor-related pathways.
Basta-Kaim, A; Budziszewska, B; Glombik, K; Kubera, M; Lason, W; Mika, J; Piotrowska, A; Popiolek-Barczyk, K; Slusarczyk, J; Trojan, E, 2016
)
1.44
"Tianeptine is an effective antidepressant with a previously unknown mechanism of action."( The Behavioral Effects of the Antidepressant Tianeptine Require the Mu-Opioid Receptor.
Ansonoff, MA; Gassaway, MM; Grinnell, SG; Han, J; Hen, R; Javitch, JA; Kruegel, AC; Levinstein, MR; Magalong, VM; Nautiyal, KM; Pintar, JE; Sames, D; Samuels, BA, 2017
)
1.44
"Tianeptine is a clinically effective antidepressant that induces neurogenesis."( The effect of tianeptine in the prevention of radiation-induced neurocognitive impairment.
Akyurek, S; Gokce, SC; Oncu, B; Ozyigit, G; Senturk, V; Yilmaz, S, 2008
)
1.43
"Tianeptine is a clinically used antidepressant that has drawn much attention, because this compound challenges traditional monoaminergic hypotheses of depression. "( The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation.
Chattarji, S; Diamond, DM; Fuchs, E; Jay, TM; McEwen, BS; Reagan, LP; Svenningsson, P, 2010
)
2.08
"Tianeptine is an antidepressant affecting the glutamatergic system. "( The protective effect of tianeptine on Gp120-induced apoptosis in astroglial cells: role of GS and NOS, and NF-κB suppression.
Aprigliano, S; Colica, C; Iannone, M; Janda, E; Mollace, V; Muscoli, C; Musolino, V; Rotiroti, D; Sacco, I; Spedding, M; Vadalà, N; Visalli, V, 2011
)
2.12
"Tianeptine is an atypical antidepressant that exhibits structural similarities to the tricyclic antidepressants but has distinct neurochemical properties. "( The analgesic activity of intrathecal tianeptine, an atypical antidepressant, in a rat model of inflammatory pain.
Choi, JI; Jeong, HJ; Kim, WM; Lee, HG; Lee, SH; Yoon, MH, 2012
)
2.09
"Tianeptine is an unusual tricyclic antidepressant drug. "( The antinociceptive effects of intravenous tianeptine in colorectal distension-induced visceral pain in rats: the role of 5-HT₃ receptors.
Bilge, SS; Bozkurt, A; Ciftcioğlu, E; Ilkaya, F; Kesim, Y; Uzbay, TI, 2012
)
2.08
"Tianeptine is a novel anti-depressant with an efficacy equivalent to that of classical anti-depressants. "( Tianeptine's effects on spontaneous and Ca2+-induced uterine smooth muscle contraction.
Blagojević, D; Lečić-Toševski, D; Miljević, CD; Nikolić-Kokić, A; Oreščanin-Dušić, Z; Paskulin, R; Slavić, M; Spasić, MB, 2012
)
3.26
"Tianeptine is an atypical antidepressant drug that has a different mechanism of action than other antidepressants. "( Effects of fluoxetine, tianeptine and olanzapine on unpredictable chronic mild stress-induced depression-like behavior in mice.
Akar, F; Celikyurt, IK; Erden, F; Gumuslu, E; Kır, HM; Kokturk, S; Mutlu, O; Ulak, G, 2012
)
2.13
"Tianeptine is an antidepressant with proven clinical efficacy and effects on hippocampal plasticity. "( Neuroprotective properties of tianeptine: interactions with cytokines.
Brillault, J; Cecchelli, R; Dommergues, MA; Gressens, P; Kato, G; Muñoz, C; Plaisant, F; Spedding, M, 2003
)
2.05
"Tianeptine proved to be an antidepressant with balanced action, i.e., exerted thymoanaleptic, anxiolytic and activating effects."( [Clinical efficacy and tolerability of tianeptine in treatment of depression (Russian open multicenter trial)].
Avedisova, AS; Bovin, RIa; Gorodnichev, AV; Kostriukova, EG; Morozova, MA; Mosolov, SN; Panteleeva, GP; Tochilov, VA; Vertogradova, OP, 2003
)
1.31
"Tianeptine (tianeptine) is an effective antidepressant that prevents and even reverses the actions of stress and glucocorticoids on dendritic remodeling in an animal model of chronic stress."( Structural plasticity and tianeptine: cellular and molecular targets.
Magarinos, AM; McEwen, BS; Reagan, LP, 2002
)
1.34
"Tianeptine is an antidepressant with 5-HT reuptake enhancing properties (i.e."( The effects of tianeptine or paroxetine on 35% CO2 provoked panic in panic disorder.
Griez, E; Schruers, K, 2004
)
1.4
"Tianeptine is a serotonin-uptake enhancer drug whose antidepressant effectiveness is based on its ability to reduce rather than increase serotonin availability at the synaptic cleft. "( Acute effects of tianeptine on circulating neurotransmitters and cardiovascular parameters.
Baez, S; Hernández, G; Lechin, F; Orozco, B; Rodríguez, S; van der Dijs, B, 2006
)
2.12
"Tianeptine is an antidepressant agent like the selective serotonin reuptake inhibitors (SSRIs). "( [A case of tianeptine abuse].
Cakmak, D; Erim, R; Saatçioğlu, O, 2006
)
2.17
"Tianeptine is a new antidepressant drug with less adverse effects on sexual functions."( Tianeptine can be effective in men with depression and erectile dysfunction.
Abu El-Magd, S; Atteya, A; El-Shafey, H; Fathy, A; Hassanein, A; Shamloul, R, 2006
)
2.5
"Tianeptine is an atypical antidepressant drug. "( Tianeptine: potential influences on neuroplasticity and novel pharmacological effects.
Uzbay, TI, 2008
)
3.23
"Tianeptine is a novel antidepressant agent, both structurally (modified tricyclic) and in terms of its pharmacodynamic profile. "( Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression.
Benfield, P; Wilde, MI, 1995
)
3.18
"Tianeptine is an atypical tricyclic antidepressant that facilitates serotonin (5-HT) reuptake. "( Tianeptine treatment induces regionally specific changes in monoamines.
Frankfurt, M; Luine, VN; McEwen, BS; McKittrick, CR, 1995
)
3.18
"Tianeptine is a substance enhancing the serotonir uptake while sertraline and clomipramine inhibit it. "( Effects of tianeptine, sertraline and clomipramine on brain serotonin metabolism: a voltammetric approach in the rat.
Cespuglio, R; Debilly, G; Jouvet, M; Marinesco, S; Poncet, L, 1996
)
2.13
"Tianeptine is a novel antidepressant with a reverse mode of action to that of the selective serotonin reuptake inhibitors yet with proven efficacy and safety."( [Treatment with tianeptine for depressive disorders in the elderly].
Alvarez, E; Cervera, S; Dourdil, F; Giner, J; Guerrero, J; Montes, JM; Saiz Ruiz, J; Seva, A,
)
1.2
"2. Tianeptine is a novel antidepressant with a reverse mode of action to that of the selective serotonin reuptake inhibitors yet with proven efficacy and safety."( Tianeptine therapy for depression in the elderly.
Alvarez, E; Cervera, S; Dourdil, F; Giner, J; Guerrero, J; López-Ibor, JJ; Montes, JM; Saiz-Ruiz, J; Seva, A, 1998
)
2.26
"Tianeptine also functions as a therapeutic tool since it reversed the already established hippocampal atrophy caused by treatment with corticosterone for 3 weeks."( Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress.
Deslandes, A; Magariños, AM; McEwen, BS, 1999
)
1.02
"Tianeptine is a novel antidepressant which enhances the reuptake of serotonin (5-HT). "( Effects of tianeptine and mianserin on car driving skills.
Hindmarch, I; Ridout, F, 2001
)
2.14
"Tianeptine is an antidepressant agent with a novel neurochemical profile. "( Tianeptine: a review of its use in depressive disorders.
Ormrod, D; Spencer, CM; Wagstaff, AJ, 2001
)
3.2
"Tianeptine (TIA) is an antidepressant drug which enhances the reuptake of serotonin but, in contrast to tricyclics, shows no affinity for neurotransmitter receptors. "( Effect of repeated treatment with tianeptine and fluoxetine on the central alpha(1)-adrenergic system.
Dlaboga, D; Dziedzicka-Wasylewska, M; Maj, J; Rogóz, Z; Skuza, G, 2001
)
2.03
"Tianeptine (TIA) is an antidepressant drug that has been shown to decrease extracellular serotonin level and reveals no affinity for neurotransmitter receptors. "( Effect of repeated treatment with tianeptine and fluoxetine on central dopamine D(2) /D(3) receptors.
Dlaboga, D; Dziedzicka-Wasylewska, M; Maj, J; Rogoz, Z; Skuza, G, 2002
)
2.04
"Tianeptine is an effective antidepressant with original neurochemical properties. "( [Efficacy of tianeptine in the treatment of psychasthenia. A study versus placebo].
Deniker, P; Ganry, H; Grivois, H,
)
1.94
"Tianeptine is a tricyclic antidepressant with an unusual chemical structure (a long lateral chain grafted on to a substituted dibenzothiazepin nucleus), and with biochemical and animal-behavioural properties which are strikingly different from those of classical tricyclics. "( Neurochemical and pharmacological properties of tianeptine, a novel antidepressant.
Kamoun, A; Labrid, C; Mocaër, E, 1992
)
1.98
"Tianeptine is a new tricyclic compound whose principal action is to increase the reuptake of serotonin. "( Long-term use of tianeptine in 380 depressed patients.
Dufour, H; Ganry, H; Guelfi, JD; Kamoun, A; Lôo, H; Malka, R; Marey, C; Olié, JP; Scharbach, H; Tignol, J, 1992
)
2.07
"Tianeptine is a novel tricyclic agent that activates the neuronal uptake of serotonin (5-hydroxytryptamine, 5-HT). "( Influence of the novel antidepressant tianeptine on neurochemical, neuroendocrinological, and behavioral effects of stress in rats.
Baudrie, V; Broqua, P; Chaouloff, F; Laude, D, 1992
)
2
"Tianeptine is a tricyclic antidepressant which enhances serotonin uptake in certain brain areas. "( Comparative study of the effects of tianeptine and other antidepressants on the activity of medial septal neurons in rats anesthetized with urethane.
Bassant, MH; Jazat, F; Lamour, Y; Lee, BH, 1991
)
2
"Tianeptine is a new tricyclic antidepressant. "( [Therapeutic effects of tianeptine in patients with depression and anxiety disorders with or without associated alcoholism].
Delalleau, B; Ganry, H; Kamoun, A; Marey, C, 1991
)
2.03
"Tianeptine is a novel antidepressant which uniquely facilitates 5-hydroxytryptamine (5-HT) uptake. "( The effects of tianeptine on wet-dog shakes, fore-paw treading and a flexor reflex in rats are consistent with enhancement of 5-hydroxytryptamine uptake.
Koshikawa, N; Mocaër, E; Stephenson, JD, 1991
)
2.08
"Tianeptine is a new antidepressant drug reported to enhance serotonin (5-hydroxytryptamine [5-HT]) uptake in rat brain. "( Increased serotonin platelet uptake after tianeptine administration in depressed patients.
Chamba, G; Ferber, C; Ferry, N; Flachaire, E; Kamoun, A; Lemoine, P; Mocaër, E; Quincy, C; Renaud, B; Sassard, J, 1991
)
1.99
"Tianeptine is a novel tricyclic antidepressant which, in marked contrast to other antidepressants, increases the uptake of 5-HT in brain tissue and blood platelet preparations ex vivo. "( The effect of the novel antidepressant tianeptine on the concentration of 5-hydroxytryptamine in rat hippocampal dialysates in vivo.
Curzon, G; O'Connell, MT; Sarna, GS; Whitton, PS, 1991
)
1.99
"Tianeptine is a new antidepressant with a tricyclic molecular structure. "( [Patients treated for one year with tianeptine. Results at one of the centers of South-Eastern France].
Duclaud, L; Dufour, H; Leibovici, G; Magnan, M; Masquin, L; Rouzier, G; Souche, A; Vallée, D; Yzombard, G; Zekri, JR,
)
1.85
"Tianeptine is a new tricyclic antidepressant which is metabolized mainly by beta-oxidation of its heptanoic side chain. "( Tianeptine, a new tricyclic antidepressant metabolized by beta-oxidation of its heptanoic side chain, inhibits the mitochondrial oxidation of medium and short chain fatty acids in mice.
Deschamps, D; Freneaux, E; Fromenty, B; Labbe, G; Larrey, D; Letteron, P; Pessayre, D, 1989
)
3.16
"Tianeptine is a new antidepressant effective against anxiety accompanying mood disturbances. "( Antidepressant and anxiolytic activities of tianeptine: an overview of clinical trials.
Defrance, R; Kamoun, A; Marey, C, 1988
)
1.98
"Tianeptine is a new effective antidepressant drug. "( Neurochemical profile of tianeptine, a new antidepressant drug.
Kato, G; Weitsch, AF, 1988
)
2.02
"Tianeptine is an antidepressant characterized by a 3-chlorodibenzothiazepin nucleus and an aminoheptanoic side chain."( Structure-activity relationships of tricyclic antidepressants, with special reference to tianeptine.
Kamoun, A; Labrid, C; Malen, C; Mocaër, E; Moleyre, J; Poignant, JC, 1988
)
1.22
"Tianeptine is a clinically effective antidepressant, not chemically related to classical tricyclic compounds. "( [Electrophysiological study of tianeptine, a new enhancer of serotonin uptake with antidepressant activity].
Lejeune, F; Poignant, JC; Reure, H, 1988
)
2
"Tianeptine is a tricyclic agent provided with antidepressant activity in experimental models and in clinical trials. "( Tianeptine, a selective enhancer of serotonin uptake in rat brain.
Garattini, S; Mennini, T; Mocaer, E, 1987
)
3.16

Effects

Tianeptine has a positive influence on mental and somatic status of patients with UC. Tianeptine, which has a mechanism of action opposite to that of SSRIs, necessitated a re-evaluation of the biochemical basis of depression.

Tianeptine (Tian) has been widely used in treating mood and anxiety disorders, and recently as a nootropic to improve cognitive performance. Tianeptine, which has a mechanism of action opposite to that of SSRIs, necessitated a re-evaluation of the biochemical basis of depression.

ExcerptReferenceRelevance
"The tianeptine has a short half-life, making it difficult to design for sustained-release tablets and achieve bioequivalence with the tianeptine immediate-release tablet (Stablon"( In Vitro-In Vivo Correlation of Tianeptine Sodium Sustained-Release Dual-Layer Tablets.
Kim, JE; Lee, YJ, 2022
)
1.49
"Tianeptine has a positive influence on mental and somatic status of patients with UC. "( [Evaluation of the influence of tianeptine on the psychosomatic status of patients with ulcerative colitis in remission].
Chojnacki, C; Chojnacki, J; Florkowski, A; Klupinska, G; Pawłowicz, M; Wachowska-Kelly, P; Walecka-Kapica, E, 2011
)
2.1
"Tianeptine, which has a mechanism of action opposite to that of SSRIs, necessitated a re-evaluation of the biochemical basis of depression and revealed that it cannot be explained by the monoamine hypothesis only."( Tianeptine: potential influences on neuroplasticity and novel pharmacological effects.
Uzbay, TI, 2008
)
2.51
"Tianeptine has a comparatively favourable pharmacokinetic profile."( Tianeptine: a review of its use in depressive disorders.
Ormrod, D; Spencer, CM; Wagstaff, AJ, 2001
)
2.47
"Tianeptine (Tian) has been used as antidepressant with anxiolytic properties and recently as a nootropic to improve cognitive performance, but its mechanism of action is unknown."( Tianeptine modulates synaptic vesicle dynamics and favors synaptic mitochondria processes in socially isolated rats.
Borgwardt, S; Costina, V; Djordjević, S; Filipović, D; Findeisen, P; Gass, P; Inta, D; Perić, I, 2021
)
2.79
"The tianeptine has a short half-life, making it difficult to design for sustained-release tablets and achieve bioequivalence with the tianeptine immediate-release tablet (Stablon"( In Vitro-In Vivo Correlation of Tianeptine Sodium Sustained-Release Dual-Layer Tablets.
Kim, JE; Lee, YJ, 2022
)
1.49
"Tianeptine (Tian) has been widely used in treating mood and anxiety disorders, and recently as a nootropic to improve cognitive performance. "( Tianeptine Enhances Energy-related Processes in the Hippocampal Non-synaptic Mitochondria in a Rat Model of Depression.
Costina, V; Filipović, D; Findeisen, P; Gass, P; Perić, I, 2020
)
3.44
"Tianeptine has a positive influence on mental and somatic status of patients with UC. "( [Evaluation of the influence of tianeptine on the psychosomatic status of patients with ulcerative colitis in remission].
Chojnacki, C; Chojnacki, J; Florkowski, A; Klupinska, G; Pawłowicz, M; Wachowska-Kelly, P; Walecka-Kapica, E, 2011
)
2.1
"Thus tianeptine has neuroprotective effects against hypoxia in tissue culture and against the deleterious effects of cytokines in cortex and white matter, but not against NMDA receptor-mediated excitotoxicity."( Neuroprotective properties of tianeptine: interactions with cytokines.
Brillault, J; Cecchelli, R; Dommergues, MA; Gressens, P; Kato, G; Muñoz, C; Plaisant, F; Spedding, M, 2003
)
1.06
"Tianeptine, which has a mechanism of action opposite to that of SSRIs, necessitated a re-evaluation of the biochemical basis of depression and revealed that it cannot be explained by the monoamine hypothesis only."( Tianeptine: potential influences on neuroplasticity and novel pharmacological effects.
Uzbay, TI, 2008
)
2.51
"Tianeptine also has beneficial effects in the amygdala and cortex and can reverse the effects of stress on neuronal and synaptic functioning."( Neurobiological and clinical effects of the antidepressant tianeptine.
Kasper, S; McEwen, BS, 2008
)
1.31
"Tianeptine has been shown to be active in the treatment of depression in patients with history of alcohol abuse or dependence."( Tianeptine and alcohol dependence.
Delalleau, B; Favre, JD; Guelfi-Sozzi, C; Lôo, H, 1997
)
2.46
"Tianeptine has a comparatively favourable pharmacokinetic profile."( Tianeptine: a review of its use in depressive disorders.
Ormrod, D; Spencer, CM; Wagstaff, AJ, 2001
)
2.47
"Tianeptine has been reported to improve both working and reference memories in rodents."( Comparative study of the effects of tianeptine and other antidepressants on the activity of medial septal neurons in rats anesthetized with urethane.
Bassant, MH; Jazat, F; Lamour, Y; Lee, BH, 1991
)
1.28
"Tianeptine has no affinity for alpha 1 adrenergic and H1 antihistaminic receptors; this affinity is responsible in a large part for the sedative anxiolytic properties of antidepressants."( Position of tianeptine among antidepressive chemotherapies.
Deniker, P; Lôo, H, 1988
)
1.38
"Tianeptine has novel behavioral effects."( Pharmacological antidepressive effects and tianeptine-induced 5-HT uptake increase.
Kamoun, A; Mocaër, E; Rettori, MC, 1988
)
1.26

Actions

Tianeptine is known to enhance serotonin uptake. We compared it with fluoxetine, an inhibitor of 5-HT reuptake, as well as with desipramine. Tianeptine did not produce orthostatic hypotension or increase heart rate.

ExcerptReferenceRelevance
"Tianeptine was shown to inhibit the ion currents induced by the inhibitory neurotransmitters GABA and glycine as well as the inwardly rectifying K(+) current induced by 5-HT and 8-hydroxy-2 (di-n-propylamino) tetraline hydrobromide (8-OH-DPAT), a 5-HT(1A) agonist."( Modulation of tianeptine on ion currents induced by inhibitory neurotransmitters in acutely dissociated dorsal raphe neurons of Sprague-Dawley rats.
Chung, JH; Kim, CJ; Kim, EH; Kim, SA; Kim, YJ; Shin, MC, 2002
)
1.4
"Tianeptine did not cause any significant change in the locomotor activity of the rats."( Investigation of the effects of tianeptine and fluoxetine on pentylenetetrazole-induced seizures in rats.
Ceyhan, M; Kayir, H; Uzbay, IT, 2005
)
1.33
"Tianeptine is known to enhance serotonin uptake, and we compared it with fluoxetine, an inhibitor of 5-HT reuptake, as well as with desipramine."( Prevention of stress-induced morphological and cognitive consequences.
Conrad, CD; Frankfurt, M; Kuroda, Y; Magarinos, AM; McEwen, BS; McKittrick, C, 1997
)
1.02
"Tianeptine inhibits the increase in the tryrosine hydroxylase messenger RNA, also induced by isolation stress."( [Stress and hippocampus. An update on current knowledge].
McEwen, BS, 1991
)
1
"Tianeptine did not produce orthostatic hypotension or increase heart rate."( Lack of cardiovascular side effects of the new tricyclic antidepressant tianeptine. A double-blind, placebo-controlled study in young healthy volunteers.
d'Hooge, D; Delcourt, E; Douchamps, J; Dulcire, C; Herchuelz, A; Juvent, M; Kostucki, W, 1990
)
1.23
"Tianeptine does not cause sedation and sleeping troubles."( [Tianeptine, an uncommon psychotropic drug].
Kamoun, A; Labrid, C; Mocaër, E; Perret, L; Poirier, JP,
)
1.76
"Tianeptine did not inhibit monoamine oxidase (MAO), MAOA or MAOB activity."( Neurochemical profile of tianeptine, a new antidepressant drug.
Kato, G; Weitsch, AF, 1988
)
1.3

Treatment

Tianeptine caused microtubule bundling and specific degradation of cytoplasmic dynein. Tianeptine can pose a risk for addicted patients in terms of high doses as well as tolerability.

ExcerptReferenceRelevance
"Tianeptine-treated subjects were less accurate at identifying facial expressions, though this was not valence specific."( Tianeptine in an experimental medicine model of antidepressant action.
Cooper, CM; Cowen, PJ; Harmer, CJ; Whiting, DA, 2015
)
2.58
"Tianeptine treatment increased glutathione peroxidase (GSH-Px) and catalase (CAT) activities in spontaneous and Ca2+-stimulated uteri."( Tianeptine's effects on spontaneous and Ca2+-induced uterine smooth muscle contraction.
Blagojević, D; Lečić-Toševski, D; Miljević, CD; Nikolić-Kokić, A; Oreščanin-Dušić, Z; Paskulin, R; Slavić, M; Spasić, MB, 2012
)
2.54
"Tianeptine treatment reversed the stress effects for the genes analyzed."( Regulation of hippocampal gene expression is conserved in two species subjected to different stressors and antidepressant treatments.
Alfonso, J; Frasch, AC; Frick, LR; Genaro, AM; Palumbo, ML; Silberman, DM, 2006
)
1.06
"Tianeptine treatment of OB rats significantly inhibited peridodontal bone loss, normalized behavioural responses, enhanced TGF-1beta levels, and abolished TNF-alpha decrease, but did not attenuate the increased corticosterone response and the decreased hippocampal GR expression."( Enhanced susceptibility to periodontitis in an animal model of depression: reversed by chronic treatment with the anti-depressant tianeptine.
Breivik, T; Fonnum, F; Gjermo, P; Gundersen, Y; Murison, R; Myhrer, T; Opstad, PK; Osmundsen, H; von Hörsten, S, 2006
)
1.26
"Tianeptine treatment was given to 55 patients (25-37.5 mg/day for 3.3 months), 58 patients were in control group."( [Treatment of depression in patients with myocardial infarction with tianeptine].
Kachkovskiĭ, MA; Kriukov, NN, 2006
)
1.29
"Tianeptine treatment of depression in patients with MI in 3-7 days led to decrease of feeling of depression and lowering of anxiety. "( [Treatment of depression in patients with myocardial infarction with tianeptine].
Kachkovskiĭ, MA; Kriukov, NN, 2006
)
2.01
"Tianeptine treatment of depression in patients with MI is effective, safe, well tolerated by patients and allows to decrease number of hospitalizations because of complications of cardiovascular diseases during 1 year."( [Treatment of depression in patients with myocardial infarction with tianeptine].
Kachkovskiĭ, MA; Kriukov, NN, 2006
)
2.01
"Tianeptine treatment (10 mg/kg/day) prevented the stress-induced atrophy of dendrites of CA3 pycamidal neurons, whereas neither fluoxetine (10 mg/kg/day) nor desipramine (10 mg/kg/day) had any effect."( Prevention of stress-induced morphological and cognitive consequences.
Conrad, CD; Frankfurt, M; Kuroda, Y; Magarinos, AM; McEwen, BS; McKittrick, C, 1997
)
1.02
"Tianeptine treatment did not prevent the effects of stress to increase adrenal/body weight ratio, nor did it prevent the effects of stress to decrease body weight gain, indicating that its actions are not mediated solely by effects on stress-induced secretion of corticosterone."( Tianeptine attenuates stress-induced morphological changes in the hippocampus.
Cameron, H; Daniels, DC; Gould, E; McEwen, BS; Watanabe, Y, 1992
)
2.45
"Treatment with tianeptine caused microtubule bundling and specific degradation of cytoplasmic dynein, a retrograde microtubule motor that mediates various microtubule-dependent processes during interphase and mitosis, in the rat pheochromocytoma PC12 cells."( Tianeptine interferes with microtubule organization and hormone secretion of pheochromocytoma cells.
Hall, J; Hensley, K; Jain, P; Jang, Y; Makani, V; Park, JJ; Qamar, K, 2013
)
2.17
"Treatment with tianeptine prior to acute stress prevented this spatial deficit."( Different effects of tianeptine pretreatment in rats exposed to acute stress and repeated severe stress.
Kasar, M; Mengi, M; Yildirim, EA; Yurdakos, E, 2009
)
1.01
"Treatment with tianeptine can pose a risk for addicted patients in terms of high doses as well as tolerability."( [A case of tianeptine abuse].
Cakmak, D; Erim, R; Saatçioğlu, O, 2006
)
1.06

Toxicity

Tianeptine appears to be as effective and as safe as paroxetine for the ambulatory treatment of major depression. Preclinical data regarding the abuse potential and other opioid-like adverse effects of tianptine at supratherapeutic doses are sparse.

ExcerptReferenceRelevance
" With regard to the clinical tolerance of tianeptine, somatic complaints were rarely reported and adverse events necessitating premature termination of treatment (4."( Clinical safety and efficacy of tianeptine in 1,858 depressed patients treated in general practice.
Dulcire, C; Guelfi, JD; Le Moine, P; Tafani, A, 1992
)
0.83
" These results confirm previous findings that tianeptine is an effective antidepressant with a lower side effect profile than amitriptyline."( The efficacy and safety of tianeptine in the treatment of depressive disorder: results of a controlled double-blind multicentre study vs. amitriptyline.
Aguglia, E; Bertolino, A; Casacchia, M; Ciani, N; Invernizzi, G; Marchesi, GF; Nardini, M; Rapisarda, V, 1994
)
0.84
"Tianeptine appears to be as effective and as safe as paroxetine for the ambulatory treatment of major depression."( Efficacy and safety of tianeptine in major depression: evidence from a 3-month controlled clinical trial versus paroxetine.
Azoulay, P; Septien, L; Waintraub, L, 2002
)
2.07
" No adverse effects with frequency > or = 10%, were registered."( Efficacy, tolerability and safety of tianeptine in special populations of depressive patients.
Britvić, D; Cvetić, T; Damjanović, A; Jasović-Gasić, M; Marić, NP; Prostran, M; Vuković, O, 2009
)
0.63
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Acute toxicity study conducted on Swiss albino mice showed that matrix tablets were safe and non-toxic, as no changes in physical activity and functions of organs were observed."( Exploring the potential of tianeptine matrix tablets: Synthesis, physico-chemical characterization and acute toxicity studies.
Aslam, F; Malik, NS; Masood-Ur-Rehman, -; Naeem, MA; Riaz, M; Salam, NA; Shahiq-Uz-Zaman, -, 2020
)
0.86
" Preclinical data regarding the abuse potential and other opioid-like adverse effects of tianeptine at supratherapeutic doses are sparse."( Opioid-like adverse effects of tianeptine in male rats and mice.
Akbarali, HI; Baird, TR; Dewey, WL; Elder, H; Kang, M; Marsh, SA; Negus, SS; Peace, MR; Poklis, JL; Santos, EJ, 2022
)
1.23
"The present study evaluated tianeptine in a rat model of abuse potential assessment and in mouse models of motor, gastrointestinal, and respiratory adverse effects."( Opioid-like adverse effects of tianeptine in male rats and mice.
Akbarali, HI; Baird, TR; Dewey, WL; Elder, H; Kang, M; Marsh, SA; Negus, SS; Peace, MR; Poklis, JL; Santos, EJ, 2022
)
1.3
" Nonetheless, tianeptine produces MOR agonist-like acute adverse effects that include motor impairment, constipation, and respiratory depression."( Opioid-like adverse effects of tianeptine in male rats and mice.
Akbarali, HI; Baird, TR; Dewey, WL; Elder, H; Kang, M; Marsh, SA; Negus, SS; Peace, MR; Poklis, JL; Santos, EJ, 2022
)
1.37

Pharmacokinetics

The predictive ability of population pharmacokinetic parameters of tianeptine, obtained from a mixed effect analysis of pre-marketing studies, was evaluated. 12 healthy male volunteers entered a balanced three-way double blind study.

ExcerptReferenceRelevance
"A balanced 3 way cross-over study involving 12 young healthy volunteers (6 men and 6 women) was used to determine the pharmacokinetic parameters of the antidepressant tianeptine following a single dose administered by oral and intravenous route."( The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans--influence of alcohol co-administration.
Defrance, R; Hopkins, R; Salvadori, C; Ward, C, 1990
)
0.74
"To assess if any pharmacokinetic or pharmacodynamic interaction at steady-state occurs between the new antidepressant tianeptine and a benzodiazepine (oxazepam) following multiple oral dosing of both drugs, 12 healthy male volunteers entered a balanced three-way double blind cross-over study."( Pharmacokinetic and pharmacodynamic interaction between the antidepressant tianeptine and oxazepam at steady-state.
Delalleau, B; Halliday, MS; Holt, BL; Langley, SJ; Mullins, FG; Rowland, M; Salvadori, C; Toon, S, 1990
)
0.72
" Pharmacokinetic parameters for tianeptine and its C5 acid analogue metabolite (MC5 metabolite) were estimated by non-compartmental analysis."( Tianeptine and its main metabolite pharmacokinetics in chronic alcoholism and cirrhosis.
Barrucand, D; Defrance, R; Paille, F; Royer, RJ; Royer-Morrot, MJ; Salvadori, C; Schmitt, J, 1989
)
2
"Tianeptine is a novel antidepressant agent, both structurally (modified tricyclic) and in terms of its pharmacodynamic profile."( Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression.
Benfield, P; Wilde, MI, 1995
)
3.18
"The predictive ability of population pharmacokinetic parameters of tianeptine, obtained from a mixed effect analysis of pre-marketing pharmacokinetic studies, was evaluated using tianeptine plasma concentrations obtained during a large multi-center post-marketing surveillance study."( Predictive performance of population pharmacokinetic parameters of tianeptine as applied to plasma concentrations from a post-marketing study.
Fiedler-Kelly, JB; Grasela, TH; Jochemsen, R; Loo, H; Marey, C; Salvadori, C, 1993
)
0.76
" This method, validated according to the criteria established by the Journal of Chromatography B, was applied to the determination of tianeptine and MC5-metabolite in human plasma in pharmacokinetic studies."( High-performance liquid chromatographic determination of tianeptine in plasma applied to pharmacokinetic studies.
Desroches, R; Gaulier, JM; Lacassie, E; Lachatre, G; Marquet, P, 2000
)
0.76
"5 mg and the branded (reference) formulation Stablon® with regard to their pharmacokinetic profiles."( Pharmacokinetic and bioequivalence assessment of two formulations of tianeptine sodium in healthy male volunteers.
Kim, BH; Zheng, R, 2014
)
0.64
"The pharmacokinetic parameters were assessed in the 40 subjects who completed the study."( Pharmacokinetic and bioequivalence assessment of two formulations of tianeptine sodium in healthy male volunteers.
Kim, BH; Zheng, R, 2014
)
0.64
"The test and reference formulations of tianeptine were bioequivalent with regard to the pharmacokinetic parameters of Cmax and AUC(last)."( Pharmacokinetic and bioequivalence assessment of two formulations of tianeptine sodium in healthy male volunteers.
Kim, BH; Zheng, R, 2014
)
0.91
" Following an intravenous administration of tianeptine pharmacokinetic parameters were calculated by non-compartmental analysis."( Pharmacokinetic study of tianeptine and its active metabolite MC5 in rats following different routes of administration using a novel liquid chromatography tandem mass spectrometry analytical method.
Fedak, FA; Pociecha, K; Szafarz, M; Wencel, A; Wlaź, P; Wyska, E, 2018
)
1.05

Compound-Compound Interactions

ExcerptReferenceRelevance
" Literature search showed no reports of MAOIs combined with tianeptine."( Tianeptine in combination with monoamine oxidase inhibitors for major depressive disorder.
Tobe, EH, 2012
)
2.06

Bioavailability

Alcohol co-administration lowered tianeptine plasma levels by about 30% but did not affect those of the MC5 metabolite. Bioavailability of tianptine after its intraperitoneal administration was 69%.

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Alcohol co-administration decreased tianeptine absorption rate and lowered tianeptine plasma levels by about 30% but did not affect those of the MC5 metabolite."( The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans--influence of alcohol co-administration.
Defrance, R; Hopkins, R; Salvadori, C; Ward, C, 1990
)
0.81
" Absolute bioavailability is 99 +/- 29%."( Pharmacokinetic and metabolic parameters of tianeptine in healthy volunteers and in populations with risk factors.
Albin, H; Barrucand, D; Kamoun, A; Royer, RJ; Salvadori-Failler, C, 1988
)
0.54
" It is not subject to first-pass hepatic metabolism, has high bioavailability and limited distribution, and is rapidly eliminated."( Tianeptine: a review of its use in depressive disorders.
Ormrod, D; Spencer, CM; Wagstaff, AJ, 2001
)
1.75
" The promising orodispersible film based on lycoat NG73 (F1); showing the greatest drug dissolution, satisfactory in vitro disintegration time and physico-mechanical properties that are suitable for orodispersible films, was evaluated for its bioavailability compared with a reference marketed product (Stablon® tablets) in rabbits."( Formulation of a novel tianeptine sodium orodispersible film.
Abd El-Malak, NS; El-Malak, NS; El-Setouhy, DA, 2010
)
0.67
" Bioavailability of tianeptine after its intraperitoneal administration was 69%."( Pharmacokinetic study of tianeptine and its active metabolite MC5 in rats following different routes of administration using a novel liquid chromatography tandem mass spectrometry analytical method.
Fedak, FA; Pociecha, K; Szafarz, M; Wencel, A; Wlaź, P; Wyska, E, 2018
)
1.11

Dosage Studied

Acute tianeptine attenuated extinction learning as well as the recall of extinction memory, which underscores that acute dosing with the drug could alter learning during EBT. Tianeptine dosage was always used higher than recommended and the drug was taken in association with other psychotropes.

ExcerptRelevanceReference
" Tianeptine was well tolerated in depressed patients and induced no significant changes at the current dosage in treatment periods from three-months to one-year even in elderly patients, patients with cardiovascular abnormalities or alcoholic patients."( [Cardiovascular tolerance to tianeptine].
Delalleau, B; Ganry, H; Lapeyre, G; Lasnier, C; Marey, C, 1991
)
1.48
" Multiple dosing of tianeptine was well tolerated; no accumulation of the unchanged drug was observed."( Pharmacokinetics of the antidepressant tianeptine at steady state in the elderly.
Demotes-Mainard, F; Galley, P; Manciet, G; Salvadori, C; Vinson, G, 1991
)
0.87
"To assess if any pharmacokinetic or pharmacodynamic interaction at steady-state occurs between the new antidepressant tianeptine and a benzodiazepine (oxazepam) following multiple oral dosing of both drugs, 12 healthy male volunteers entered a balanced three-way double blind cross-over study."( Pharmacokinetic and pharmacodynamic interaction between the antidepressant tianeptine and oxazepam at steady-state.
Delalleau, B; Halliday, MS; Holt, BL; Langley, SJ; Mullins, FG; Rowland, M; Salvadori, C; Toon, S, 1990
)
0.72
" Patients were treated in monotherapy for 42 days with a mean dosage of 3 tablets per day corresponding to 37."( Efficacy of tianeptine in anxious-depressed patients: results of a controlled multicenter trial versus amitriptyline.
Dreyfus, JF; Guelfi, JD; Pichot, P, 1989
)
0.66
" On the basis of this study, it appears unnecessary to modify the proposed dosage regimen used in clinical trials (tianeptine sodium salt 12."( Tianeptine and its main metabolite pharmacokinetics in chronic alcoholism and cirrhosis.
Barrucand, D; Defrance, R; Paille, F; Royer, RJ; Royer-Morrot, MJ; Salvadori, C; Schmitt, J, 1989
)
1.93
" In renal failure, and in the elderly, studies have revealed a 1-h prolongation of elimination half-life which suggests that the dosage should be limited to two tablets per day in such cases."( Pharmacokinetic and metabolic parameters of tianeptine in healthy volunteers and in populations with risk factors.
Albin, H; Barrucand, D; Kamoun, A; Royer, RJ; Salvadori-Failler, C, 1988
)
0.54
" Higher dosage (25 mg."( [Electrophysiological study of tianeptine, a new enhancer of serotonin uptake with antidepressant activity].
Lejeune, F; Poignant, JC; Reure, H, 1988
)
0.56
" Studies represented a combination of single dose and multiple dosing at steady-state."( Development of a population pharmacokinetic database for tianeptine.
Fiedler-Kelly, JB; Grasela, TH; Jochemsen, R; Marey, C; Salvadori, C, 1993
)
0.53
"5 mg, indicating that though increasing dosage does not improve efficacy, there is no risk of poorer acceptability."( [Major depressive episodes in patients over 70 years of age. Evaluation of the efficiency and acceptability of tianeptine and mianserin].
Audrain, S; Brion, S; de Bodinat, C, 1996
)
0.51
" After a medical prescription of the recommended dosage of 12."( [Abuse of tianeptine. A case report].
Bizouard, P; Bonin, B; Regina, W; Sechter, D; Vandel, P,
)
0.53
" While this offers advantages for tianeptine over the tricyclic antidepressant agents in terms of dose titration, treatment changes and potential drug interactions, its rapid elimination makes adherence to dosage schedules more important."( Tianeptine: a review of its use in depressive disorders.
Ormrod, D; Spencer, CM; Wagstaff, AJ, 2001
)
2.03
" Secondary criteria confirmed the antidepressant efficacy of both medications, with no difference between tianeptine and paroxetine (Hamilton Depression Rating Scale global score at endpoint, Clinical Global Impression final scores, number of responders, delay-to-response, rate of dosage doubling at day 21)."( Efficacy and safety of tianeptine in major depression: evidence from a 3-month controlled clinical trial versus paroxetine.
Azoulay, P; Septien, L; Waintraub, L, 2002
)
0.84
" The patients received tianeptine as a monotherapy in dosage 12."( [Clinical efficacy and tolerability of tianeptine in treatment of depression (Russian open multicenter trial)].
Avedisova, AS; Bovin, RIa; Gorodnichev, AV; Kostriukova, EG; Morozova, MA; Mosolov, SN; Panteleeva, GP; Tochilov, VA; Vertogradova, OP, 2003
)
0.9
" Tianeptine dosage was always used higher than recommended and the drug was taken in association with other psychotropes."( [Misuse of tianeptine: five cases of abuse].
Auclair, V; Frimas, V; Le Boisselier, R; Leterme, L; Singlan, YS, 2003
)
1.62
" Tianeptine was assigned in dosage of 12."( [Preventive efficacy of tianeptine in recurrent depression with frequent exacerbations].
Abramova, LI; Artiukh, VV; Bannikov, GS; Gorodnichev, AV; Kostiukova, EG; Morozova, MA; Mosolov, SN; Oleĭchik, IV; Panteleeva, GP; Timofeef, IV; Vertogradova, OP, 2004
)
1.54
" All patients were treated with coaxil in dosage 12."( [A role of depression in chronic dorsalgia: approaches to therapeutic correction].
Akarachkova, ES; Vorob'eva, OV, 2004
)
0.32
" Coaxil was prescribed in dosage of 12,5 mg daily during 6 weeks."( [Coaxil treatment of primary headaches comorbid with depression].
Shavlovskaia, OA; Vorob'eva, OV, 2005
)
0.33
"Twenty patients, aged 60-69 years, with combined mild cognitive impairment, subtle depression and anxiety have been treated with coaxil (tianeptine) used in dosage 37,5 mg daily during 60 days."( [The use of coaxil (tianeptine) in the treatment of aged people with combined mild cognitive impairment and depressive-anxiety disorders].
Karpukhin, IB, 2008
)
0.87
" Acute tianeptine attenuated extinction learning as well as the recall of extinction memory, which underscores that acute dosing with the drug could alter learning during EBT."( Acute tianeptine treatment selectively modulates neuronal activation in the central nucleus of the amygdala and attenuates fear extinction.
Bontempi, B; Delagrange, P; Godsil, BP; Jay, TM; Mailliet, F; Spedding, M, 2015
)
1.35
" The PK model with a metabolite compartment developed in this study for both tianeptine and MC5 metabolite after two routes of administration may facilitate tianeptine dosage selection for the prospective pharmacological experiments."( Pharmacokinetic study of tianeptine and its active metabolite MC5 in rats following different routes of administration using a novel liquid chromatography tandem mass spectrometry analytical method.
Fedak, FA; Pociecha, K; Szafarz, M; Wencel, A; Wlaź, P; Wyska, E, 2018
)
1.01
"The main objective of the present study was to explore the potential of matrix tablets as extended release dosage form of tianeptine, using HMPC K100 as a polymer."( Exploring the potential of tianeptine matrix tablets: Synthesis, physico-chemical characterization and acute toxicity studies.
Aslam, F; Malik, NS; Masood-Ur-Rehman, -; Naeem, MA; Riaz, M; Salam, NA; Shahiq-Uz-Zaman, -, 2020
)
1.06
"We conducted a pharmacological magnetic resonance imaging study, using a randomized double-blind crossover design, to compare the effect of an acute dosage of 12."( Modulation of atypical brain activation during executive functioning in autism: a pharmacological MRI study of tianeptine.
Blainey, S; Daly, EM; Ecker, C; Findon, JL; Giampietro, V; Jelsma, A; McAlonan, G; Murphy, CM; Murphy, DGM; Robertson, DM; Rubia, K; Stoencheva, V; Wichers, RH, 2021
)
0.83
"We report a case of a middle-aged male with a 3-year history of tianeptine use who presented to an outpatient clinic looking for addiction treatment options after failed attempts at tapering his daily dosage of approximately 10 grams per day."( Microdose Induction of Buprenorphine in a Patient Using Tianeptine.
Sullivan, R; Szczesniak, L,
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
dibenzothiazepine
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency5.62340.141337.9142100.0000AID1490
TDP1 proteinHomo sapiens (human)Potency26.60860.000811.382244.6684AID686978
pregnane X nuclear receptorHomo sapiens (human)Potency7.94330.005428.02631,258.9301AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency16.93010.000229.305416,493.5996AID743075
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear receptor subfamily 1 group I member 2Homo sapiens (human)EC50 (µMol)25.43330.00203.519610.0000AID1215086; AID1215087; AID1215094
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
negative regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
signal transductionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
steroid metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of gene expressionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic catabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic transportNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
cell differentiationNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
nucleoplasmNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear bodyNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intermediate filament cytoskeletonNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (42)

Assay IDTitleYearJournalArticle
AID1215096Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis relative to rifampicin2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1215089Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis relative to rifampicin2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1215093Activation of rat PXR expressed in human HepG2 cells up to 46 uM after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1215087Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1215086Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1215095Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay relative to SR128132011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1215094Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1318844Inhibition of Wistar rat brain AChE using acetylthiochloline iodide as substrate after 30 mins by Ellman's method2016European journal of medicinal chemistry, Oct-04, Volume: 121Novel series of tacrine-tianeptine hybrids: Synthesis, cholinesterase inhibitory activity, S100B secretion and a molecular modeling approach.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1318848Toxicity in Wistar rat hippocampus assessed as LDH release at 0.1 uM relative to control2016European journal of medicinal chemistry, Oct-04, Volume: 121Novel series of tacrine-tianeptine hybrids: Synthesis, cholinesterase inhibitory activity, S100B secretion and a molecular modeling approach.
AID1318845Inhibition of human plasma BuChE using S-butyrylthiocholine iodide as substrate after 30 mins by Ellman's method2016European journal of medicinal chemistry, Oct-04, Volume: 121Novel series of tacrine-tianeptine hybrids: Synthesis, cholinesterase inhibitory activity, S100B secretion and a molecular modeling approach.
AID1247104Inhibition of human SERT expressed in HEK293 cells using 4-[4-(Dimethylamino)phenyl]-1-methyl pyridinium as substrate assessed as fluorescent intensity at 1 uM after 3 hrs relative to control2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
A novel sesquiterpene and three new phenolic compounds from the rhizomes of Acorus tatarinowii Schott.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1318849Toxicity in Wistar rat hippocampus assessed as LDH release at 0.3 uM relative to control2016European journal of medicinal chemistry, Oct-04, Volume: 121Novel series of tacrine-tianeptine hybrids: Synthesis, cholinesterase inhibitory activity, S100B secretion and a molecular modeling approach.
AID1434734Modulation of human SERT expressed in HEK293 cells at 1 uM using APP+ as substrate by fluorescence assay relative to control2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Nardonaphthalenones A and B from the roots and rhizomes of Nardostachys chinensis Batal.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (438)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (4.34)18.7374
1990's104 (23.74)18.2507
2000's152 (34.70)29.6817
2010's133 (30.37)24.3611
2020's30 (6.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 85.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index85.35 (24.57)
Research Supply Index6.34 (2.92)
Research Growth Index5.15 (4.65)
Search Engine Demand Index153.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (85.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials90 (18.95%)5.53%
Reviews0 (0.00%)6.00%
Reviews44 (9.26%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies34 (7.16%)4.05%
Observational0 (0.00%)0.25%
Observational2 (0.42%)0.25%
Other6 (100.00%)84.16%
Other305 (64.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparison of Tianeptine Versus Escitalopram for the Treatment of Depression and Cognitive Impairment in Patients With Major Depressive Disorder: A Randomized, Multicenter, Open-label Study [NCT01309776]Phase 4164 participants (Actual)Interventional2011-03-31Completed
Can Brain Activation and Connectivity Predict Treatment Response to Two Serotonergic Medications (Citalopram and Tianeptine) in Subjects With Autism Spectrum Disorders (ASD)? [NCT04145076]100 participants (Anticipated)Interventional2014-12-15Recruiting
Double Blind,Randomized, Placebo Controlled Trial of Adjunctive Tianeptine in the Treatment of Bipolar Depression [NCT00879372]Phase 313 participants (Anticipated)Interventional2009-03-31Active, not recruiting
Evaluation of the Efficacy of Perioperative Administration of Tianeptine Versus Pregabalin on Acute and Chronic Post Mastectomy Pain After Breast Cancer Surgery. A Double-Blinded Randomized Controlled Trial. [NCT05935059]90 participants (Anticipated)Interventional2023-06-21Recruiting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD) [NCT05686408]Phase 2132 participants (Actual)Interventional2023-03-02Completed
Comparison of Antidepressants in the Real-World: Retrospective Cohort Study Using Big Data [NCT04446039]405,349 participants (Actual)Observational2022-07-04Completed
Tianeptine for Treatment Resistant Depression [NCT04249596]Phase 475 participants (Anticipated)Interventional2020-10-14Recruiting
Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Tianeptine in the Treatment of Covid Fog Symptoms in Patients After COVID-19 With the Study of the Pathophysiology of the Phenomenon Using Positron Emission Tomography, Bioch [NCT06012552]Phase 2140 participants (Anticipated)Interventional2023-02-17Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]